Abbott, Zeneca, Tanabe, Ciba-Geigy, SmithKline, Marion Merrell Dow..... it's probably easier to name companies that are working on it (or have worked on it) than it is to name those who are not.
What one needs to do is find out how many of those projects have gone to clinicals, and how the clinicals, if there are any, are looking.
If you can find no evidence of advanced clinicals, you have to ask....... is TXB out in front, or did everyone else stumble across some toxicities such that they decided not to move forward.
Older biotechs often weren't sufficiently diversified, and they found themselves painted into a corner.... proceed with a project that is rather questionable, or expose the empty cupboard to the investing public. I have no bias here..... been too long since I looked at the company, and never took an in-depth look when I did. |
